Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

Shares of NASDAQ:ONVO opened at $0.49 on Monday. Organovo has a 52-week low of $0.32 and a 52-week high of $1.74. The stock has a market cap of $7.48 million, a price-to-earnings ratio of -0.46 ...

Organovo Holdings, Inc., a clinical stage biotechnology company focused on treating inflammatory bowel disease (IBD), has appointed Norman Staskey as the new Chief Financial Officer. Staskey ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm engaged in the development of treatments for inflammatory bowel disease and other conditions, announced the appointment of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm specializing in biological products with a current market capitalization of $5.5 million, announced the appointment of Norman Staskey as its ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical research ...